β2-Adrenoceptor agonists evoke rapid bronchodilatation and are the mainstay of the
treatment of asthma symptoms worldwide. The mechanism of action of this class of …

Asthma is an increasing global health problem, and many patients continue to suffer from
chronic symptoms. However, current therapy with inhaled corticosteroids and a long-acting …

Long-acting bronchodilator therapy should be considered when a COPD patient is
symptomatic. For patients whose conditions are not sufficiently controlled by monotherapy …

By 2020 chronic obstructive pulmonary disease (COPD) will be the third leading cause of
mortality and fifth leading cause of morbidity. Research over the past two decades has shed …

COPD is a widespread inflammatory respiratory disorder characterized by a progressive,
poorly reversible airflow limitation. Currently available therapies are mostly based on those …

Publisher Summary Long acting β 2-adrenoceptor agonists are a highly precedented drug
class used for the treatment of asthma and chronic obstructive pulmonary disease (COPD) …

Asthma bronchiale, an inflammatory airway disease, imposes a significant health care
problem worldwide. It is characterized by three critical phenotypic traits: intermittent and …

This paper analyses three patents, published in 2005 by Sofotec GmbH & Co. KG, for the
treatment of respiratory diseases that include asthma and chronic obstructive pulmonary …

The increasing burden of asthma in both primary and secondary care has led to extensive
research into its genetics, pathophysiology and treatment over the past few decades …

Two applications claim very closely related arylsulfonamide β2-agonists. The basic generic
claim is the same in both cases with subsidiary claims covering different permutations of the …